Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (scFv-CH1/CL) (BSCC-021)

Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-BCMA antibody variable domain is fused to CH1 and the other scFv from an anti-TACI antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can bind two receptors simultaneously. It is designed for the research of Lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

BCMA & TACI

Type

scFv-based Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

BCMA

Gene ID

608

UniProt ID

Q02223

Alternative Names

TNFRSF17; tumor necrosis factor receptor superfamily, member 17; BCM; BCMA; CD269; TNFRSF13A; tumor necrosis factor receptor superfamily member 17; B-cell maturation factor; B cell maturation antigen; B-cell maturation protein

Target 2

TACI

Gene ID

23495

UniProt ID

O14836

Alternative Names

TNFRSF13B; tumor necrosis factor receptor superfamily, member 13B; CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B; tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (scFv-CH1/CL) (BSCC-021). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (scFv-CH1/CL) (CAT#: BSCC-021)

Specifications

Targets

Customer Reviews and Q&As